Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413283 · ClinicalTrials.gov registry record · Phase 2
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study of Cancer and Non-Small Cell Lung Cancer, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 20
- Study locations
NCT00413283: Completed Phase 2 study of Cancer and Non-Small Cell Lung Cancer, sponsored by Amgen.
NCT00413283 is a Phase 2 study of Cancer and Non-Small Cell Lung Cancer that has completed, run by Amgen. The registered enrollment target is 63 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00413283, a Phase 2 study of Cancer and Non-Small Cell Lung Cancer, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.
Primary Outcome
This summary includes all treatment-emergent adverse events recorded from the start of investigational product on this study, or any worsening of adverse events initially experienced before initiation of this study.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Cisplatin
- DRUG Gemcitabine
- BIOLOGICAL Romiplostim
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Anaheim
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Rancho Mirage
- Research Site - Rancho Mirage
Florida
- Research Site - Boynton Beach
- Research Site - Boynton Beach
- Research Site - Vero Beach
- Research Site - Vero Beach
Georgia
- Research Site - Athens
- Research Site - Athens
- Research Site - Macon
- Research Site - Macon
Arizona
- Research Site - Glendale
- Research Site - Glendale
Illinois
- Research Site - Peoria
- Research Site - Peoria
Iowa
- Research Site - Sioux City
- Research Site - Sioux City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
What the finished NCT00413283 record still lists
NCT00413283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).
The record links to 8 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT00413283 names 20 study sites across 6 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00413283 about?
NCT00413283 is a clinical study titled "Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.
What is the current status of trial NCT00413283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2006-12. Estimated completion is 2009-02.
What conditions does trial NCT00413283 study?
This clinical trial studies the following conditions: Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Solid Tumors, Oncology.
What interventions are being tested in trial NCT00413283?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Romiplostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00413283?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00413283 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00413283's enrollment target sits among peer trials
63 391st of 615 higher than 224 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia